Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 185 clinical trials
featured
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.

We are currently recruiting participants for a clinical research study to evaluate the efficacy of an investigational medication in adults with Diabetic Kidney Disease.

hemoglobin a1c
kidney function tests
diabetic chronic kidney disease
diabetes
diabetic complication
  • 12 views
  • 14 Jan, 2021
  • 1 location
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted

  • 2 views
  • 05 Dec, 2020
  • 67 locations
Activity Study of Bevacizumab With Temozolomide Irinotecan for Neuroblastoma in Children

questions: does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used

refractory neuroblastoma
monoclonal antibodies
dinutuximab
topotecan
high-risk neuroblastoma
  • 57 views
  • 30 Mar, 2020
  • 10 locations
  • 0 views
  • 01 Mar, 2020
  • 1 location
25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial

Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti

bevacizumab
visual loss
detachment
adjuvant therapy
retinopathy
  • 5 views
  • 08 Nov, 2020
  • 1 location
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2VEGFR-2, Induces Transporter Pgp function in vitro. This study in patients with advanced cancer

solid tumour
advanced cancer
growth factor
cancer
  • 0 views
  • 29 Mar, 2020
  • 1 location
Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the

neutrophil count
growth factor
solid tumor
mitomycin
  • 0 views
  • 07 Nov, 2020
  • 1 location
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2VEGFRFGFRfibroblast growth factor receptor

epidermal growth factor
lung cancer
measurable disease
ct scan
g-csf
  • 0 views
  • 13 Apr, 2020
  • 6 locations
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more

  • 0 views
  • 08 Jul, 2019
  • 1 location
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP

bevacizumab
vascular endothelial growth factor
antiangiogenic therapy
vegf
blindness
  • 4 views
  • 07 Nov, 2020
  • 1 location